INmune Bio (INMB)
(Delayed Data from NSDQ)
$9.45 USD
-0.09 (-0.89%)
Updated May 31, 2024 04:00 PM ET
After-Market: $9.46 +0.01 (0.11%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
INmune Bio, Inc. [INMB]
Reports for Purchase
Showing records 41 - 60 ( 65 total )
Company: INmune Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: INmune Bio, Inc.
Industry: Medical - Biomedical and Genetics
Describes Imminent Phase 2 Trial in Newly Hospitalized COVID-19 Patients
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: INmune Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: INmune Bio, Inc.
Industry: Medical - Biomedical and Genetics
Lancet Article Emphasizes Importance of Anti-TNF Therapies For COVID-19
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: INmune Bio, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: INmune Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: INmune Bio, Inc.
Industry: Medical - Biomedical and Genetics
Targeting Breast Cancer; Adjust PT to $8.00; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: INmune Bio, Inc.
Industry: Medical - Biomedical and Genetics
Making Progress in All Programs, Novel COVID-19 Approach - Reports 4Q19
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: INmune Bio, Inc.
Industry: Medical - Biomedical and Genetics
32nd Annual Conference: Jonathan Aschoff''s Biotechnology Track Overview
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: INmune Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: INmune Bio, Inc.
Industry: Medical - Biomedical and Genetics
Receives $500,000 Grant to Develop DN-TNF as a Novel Therapy for ALS
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: INmune Bio, Inc.
Industry: Medical - Biomedical and Genetics
Management Meeting Takeaways - Undervalued Despite Several Shots on Goal
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: INmune Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: INmune Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: INmune Bio, Inc.
Industry: Medical - Biomedical and Genetics
Recently Published Preclinical Results Support Xpro1595 Rationale in AD
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: INmune Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: INmune Bio, Inc.
Industry: Medical - Biomedical and Genetics
Inhibiting Inflammation, but Sparing the Immune System - a Novel Approach
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: INmune Bio, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: INmune Bio, Inc.
Industry: Medical - Biomedical and Genetics
Advancing Pipeline Across a Broad Spectrum; Adjust PT to $11.00; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: INmune Bio, Inc.
Industry: Medical - Biomedical and Genetics
Program for Our Third Annual NASH Investor Conference, October 21, New York
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E